Boron neutron capture therapy for papillary cystadenocarcinoma in the upper lip: A case report

Kimura, Yuichi; Ariyoshi, Yasunori; Miyatake, Shin‐Ichi; Shimahara, Masashi; Kawabata, Shinji; Ono, Koji

doi:10.1016/j.ijom.2008.12.010

Cited by 19 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kimura et al reported on a 78-year-old patient with a papillary cystadenocarcinoma of the upper lip treated with BNCT using 500 mg/kg BPA as the boron carrier in two fractions with a total dose 63.4 Gy-Eq at the tumor peak. The tumor decreased by 86% at 5-month follow up, although the patient experienced acute extensive erosion (47).…”

Section: Definitive Treatment For Head and Neck Cancersmentioning

confidence: 88%

Boron Neutron Capture Therapy: A Review of Clinical Applications

et al. 2021

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is an emerging treatment modality aimed at improving the therapeutic ratio for traditionally difficult to treat tumors. BNCT utilizes boronated agents to preferentially deliver boron-10 to tumors, which, after undergoing irradiation with neutrons, yields litihium-7 and an alpha particle. The alpha particle has a short range, therefore preferentially affecting tumor tissues while sparing more distal normal tissues. To date, BNCT has been studied clinically in a variety of disease sites, including glioblastoma multiforme, meningioma, head and neck cancers, lung cancers, breast cancers, hepatocellular carcinoma, sarcomas, cutaneous malignancies, extramammary Paget’s disease, recurrent cancers, pediatric cancers, and metastatic disease. We aim to provide an up-to-date and comprehensive review of the studies of each of these disease sites, as well as a review on the challenges facing adoption of BNCT.

show abstract

Section: Definitive Treatment For Head and Neck Cancersmentioning

confidence: 88%

Boron Neutron Capture Therapy: A Review of Clinical Applications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Boron neutron capture therapy (BNCT) was recently performed in order to regulate non-resectable advanced and/or recurrent oral cancers, and its clinical utility was previously reported (3,4). However, certain patients suffer from alopecia and/or mucositis after undergoing BNCT (3,5).…”

Section: Introductionmentioning

confidence: 99%

Fluorine-18-labeled boronophenylalanine positron emission tomography for oral cancers: Qualitative and quantitative analyses of malignant tumors and normal structures in oral and maxillofacial regions

et al. 2011

View full text Add to dashboard Cite

Abstract. The present study aimed to demonstrate the features of fluorine-18-labeled boronophenylalanine positron emission tomography ( 18 F-BPA-PET) to reveal oral cancer, as well as normal structures in the oral and maxillofacial regions. We analyzed 18 F-BPA-PET findings from 8 patients with histologically confirmed recurrent and/or advanced oral cancer scheduled for boron neutron capture therapy. The capacity of 18 F-BPA-PET to delineate tumor and normal structures was assessed qualitatively and quantitatively. Tumors were easily identified as high uptake areas in all cases. Although the eyes, which were depicted as a low uptake area, and tongue musculature were readily identified, major vessels were not noted in any of the cases. Areas corresponding to the surface of the dorsum tongue to middle pharynx were expressed as high uptake areas in all of the cases. Quantitatively, tumors were expressed as the highest uptake area in 6 of the 8 cases, while the dorsum tongue had the highest uptake area in the remaining 2 cases.18 F-BPA-PET is useful in demonstrating the presence of a tumor. Thus, it is crucial to note the presence of a high uptake area corresponding to the dorsum area of the tongue when diagnosing a tumor using this technique. IntroductionFluorodeoxyglucose (FDG) positron emission tomography (PET) has recently become widely used for detecting malignant tumors of the oral cavity, particularly for the diagnosis of metastatic deposits (1). In addition, another type of PET method, methionine-basis PET, has been shown to be useful for diagnosing malignancies (2).Boron neutron capture therapy (BNCT) was recently performed in order to regulate non-resectable advanced and/or recurrent oral cancers, and its clinical utility was previously reported (3,4). However, certain patients suffer from alopecia and/or mucositis after undergoing BNCT (3,5). For planning, as well as predicting the outcome and adverse effects of this therapy, boron concentrations should be evaluated in surrounding normal structures as well as in the tumor itself, for which fluorine-18-labeled boronophenylalanine ( 18 F-BPA) PET was utilized. To the best of our knowledge, features of normal tissues and tumors in 18 F-BPA-PET images have yet to be adequately assessed. The present study therefore aimed to qualitatively and quantitatively elucidate the features of normal structures in the oral and maxillofacial regions, as well as associated tumors revealed by 18 F-BPA-PET imaging. Materials and methodsThe study evaluated 18 F-BPA-PET images obtained in examinations of 8 patients with histologically confirmed recurrent and/or advanced oral cancer, or metastatic lymphadenopathy who were scheduled for BNCT (Table I). Seven of the patients were treated with a combination of surgery, chemotherapy and radiotherapy, while 1 patient was treated with thermotherapy. All PET examinations were performed using an ECAT ACCEL (Siemens Japan Co., Tokyo, Japan) with 18 F-labeled BPA (37-55.5 MBq/10 kg of body weight) injected 45 min prior to obtaining the im...

show abstract

“…Radiation dosimetry plays a vital role in BNCT. Sustained efforts to improve the technologies and experiments of BNCT have involved incorporating it into general clinical therapy, such as melanoma, , glioblastoma, , head and neck tumor, − and metastatic cancer in the liver and lungs. , Currently, two drugs have been used in clinical practice for BNCT and evaluated in the experiment. The sodium mercaptoundecahydro-closo-dodecaborate (Na 2 B 12 H 11 SH), generally known as sodium borocaptate or BSH, was the first 10 B-containing compound designed for clinical therapy.…”

Section: Introductionmentioning

confidence: 99%

The Development of Boron Analysis and Imaging in Boron Neutron Capture Therapy (BNCT)

et al. 2022

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a selective biological targeted nuclide technique for cancer therapy. It has the following attractive features: good targeting, high effectiveness, and causes slight damage to surrounding healthy tissue compared with other traditional methods. It has been considered as one of the promising methods for the treatment of various cancers. Measuring 10B concentrations is vital for BNCT. However, the existing technology and equipment cannot satisfy the real-time and accurate measurement requirements, and more efficient methods are in demand. The development of methods and imaging applied in BNCT to help measure boron concentration is described in this review.

show abstract

Boron neutron capture therapy for papillary cystadenocarcinoma in the upper lip: A case report

Cited by 19 publications

References 7 publications

Boron Neutron Capture Therapy: A Review of Clinical Applications

Boron Neutron Capture Therapy: A Review of Clinical Applications

Fluorine-18-labeled boronophenylalanine positron emission tomography for oral cancers: Qualitative and quantitative analyses of malignant tumors and normal structures in oral and maxillofacial regions

The Development of Boron Analysis and Imaging in Boron Neutron Capture Therapy (BNCT)

Contact Info

Product

Resources

About